Effects of Cilostazol on Human Venous Smooth Muscle

Becker, Russell W.; Lusis, Eriks A.; Sohn, Richard L.; Kline, Ronald A.

doi:10.1007/s10016-005-0012-6

Cited by 8 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The phosphodiesterase inhibitors cilostazol and dipyridamole are licensed for the treatment of stroke and intermittent claudication, for which clinical trials have demonstrated modest but consistent benefits ( Reilly and Mohler, 2001 ). Cilostazol has been shown to decrease α‐granule secretion ( Inoue et al ., 1999 ) and thereby reduce platelet–leukocyte interactions ( Inoue et al ., 1999 ; Ito et al ., 2004 ) as well as acting as a vasodilator ( Becker et al ., 2005 ). In patients with peripheral arterial disease, cilostazol has not been associated with major adverse events or increased mortality although frequent but minor adverse effects have been noted ( Reilly and Mohler, 2001 ).…”

Section: Current Anti‐platelet Therapiesmentioning

confidence: 99%

Future innovations in anti‐platelet therapies

Barrett

Holbrook

Jones

et al. 2008

British J Pharmacology

140

101

View full text Add to dashboard Cite

Platelets have long been recognized to be of central importance in haemostasis, but their participation in pathological conditions such as thrombosis, atherosclerosis and inflammation is now also well established. The platelet has therefore become a key target in therapies to combat cardiovascular disease. Anti‐platelet therapies are used widely, but current approaches lack efficacy in a proportion of patients, and are associated with side effects including problem bleeding. In the last decade, substantial progress has been made in understanding the regulation of platelet function, including the characterization of new ligands, platelet‐specific receptors and cell signalling pathways. It is anticipated this progress will impact positively on the future innovations towards more effective and safer anti‐platelet agents. In this review, the mechanisms of platelet regulation and current anti‐platelet therapies are introduced, and strong, and some more speculative, potential candidate target molecules for future anti‐platelet drug development are discussed. British Journal of Pharmacology (2008) 154, 918–939; doi:; published online 21 April 2008

show abstract

Section: Current Anti‐platelet Therapiesmentioning

confidence: 99%

Future innovations in anti‐platelet therapies

Barrett

Holbrook

Jones

et al. 2008

British J Pharmacology

140

101

View full text Add to dashboard Cite

show abstract

“…Besides the antiplatelet property, cilostazol also exerts other effects, such as vasodilation, inhibition of thrombosis, decrement of triglycerides, elevation of high density lipoprotein cholesterol, inhibition of vascular smooth muscle cell growth, and neuroprotection [6][7][8][9] . It is hypothesized that cilostazol may play an important role in preventing the aggravation of cerebrovascular stenosis.…”

Section: Introductionmentioning

confidence: 99%

Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke

Guo

Lin

et al. 2009

Neurosci. Bull.

View full text Add to dashboard Cite

Objective To compare the effects of cilostazol on cerebral arteries and cerebrovascular blood flow in secondary prevention of ischemic stroke, with those of aspirin. Methods Sixty-eight patients who had ischemic stroke during the recent 1-6 months were recruited and randomized into cilostazol or aspirin group. Cerebrovascular condition was assessed by magnetic resonance angiography (MRA) and transcranial doppler ultrasonography (TCD) at the beginning of the study and after 12-month medication. Results During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found. MRA revealed that in aspirin group, the percentages of patients experiencing aggravation and attenuation of cerebrovascular condition were 3.3% and 6.7%, respectively, while in aspirin group, they were 3.3% and 10%, respectively. Moreover, TCD revealed that 26.9% of the patients in aspirin group and 14.3% of the patients in cilostazol group experienced aggravation of cerebrovascular condition. However, the systolic peak flow velocity of the previously abnormal arteries increased by 42.9% after 12-month medication of cilostazol, which was significantly higher than that after aspirin medication (27.5%) (P = 0.04).Furthermore, as a major side effect of antiplatelet therapy, the frequrency of bleeding was much less in cilostazol group (0 case in cilostazol group vs 5 in aspirin, P < 0.05). Conclusion Cilostazol is as effective as aspirin in preventing the aggravation of cerebral arteries in secondary prevention of ischemic stroke. Besides, it is more safe. Cilostazol can increase the systolic peak flow velocity of cerebral arteries, which may improve the blood supply of focal ischemia.

show abstract

“…Studies have also suggested a venodilatory effect of cilostazol, with human venous smooth muscle cells undergoing relaxation when brought in contact with therapeutic levels of cilostazol 79 …”

Section: Cardiovascular Effectsmentioning

confidence: 99%

“…78 Studies have also suggested a venodilatory effect of cilostazol, with human venous smooth muscle cells undergoing relaxation when brought in contact with therapeutic levels of cilostazol. 79 Animal studies have shown that cilostazol reduces MI size by increasing adenosine and NO levels, attenuating superoxide production, and opening the mitochondrial adenosine triphosphate-sensitive potassium channels, thus protecting the heart against ischemiareperfusion injury. 80 An animal study suggested that cilostazol may be a strong antifibrotic, antioxidant, and anti-inflammatory drug offering protection from doxorubicin-induced cardiomyopathy.…”

Section: Cardiovascular Effectsmentioning

confidence: 99%

Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications

Manolis

Manolis²,

Melita

et al. 2021

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications. It has been used over the past 25 years for improving intermittent claudication in patients with peripheral artery disease (PAD). Cilostazol also has demonstrated efficacy in patients undergoing percutaneous revascularization procedures for both PAD and coronary artery disease. In addition to its antithrombotic and vasodilating actions, cilostazol also inhibits vascular smooth muscle cell proliferation via phosphodiesterase III inhibition, thus mitigating restenosis. Accumulated evidence has shown that cilostazol, due to its "pleiotropic" effects, is a useful, albeit underutilized, agent for both coronary artery disease and PAD. It is also potentially useful after ischemic stroke and is an alternative in those who are allergic or intolerant to classical antithrombotic agents (eg, aspirin or clopidogrel). These issues are herein reviewed together with the pharmacology and pharmacodynamics of cilostazol. Large studies and meta-analyses are presented and evaluated. Current guidelines are also discussed, and the spectrum of cilostazol's actions and therapeutic applications are illustrated.

show abstract

Effects of Cilostazol on Human Venous Smooth Muscle

Cited by 8 publications

References 27 publications

Future innovations in anti‐platelet therapies

Future innovations in anti‐platelet therapies

Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke

Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications

Contact Info

Product

Resources

About